PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.52 - 1.58
1.19 - 3.37
354.5K / 984.1K (Avg.)
-1.64 | -0.94
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
33.96%
Revenue growth of 33.96% while CSIQ is flat. Bruce Berkowitz would check if a small edge can widen further.
-13.81%
Negative gross profit growth while CSIQ is at 0.00%. Joel Greenblatt would examine cost competitiveness or demand decline.
3.34%
Positive EBIT growth while CSIQ is negative. John Neff might see a substantial edge in operational management.
3.34%
Positive operating income growth while CSIQ is negative. John Neff might view this as a competitive edge in operations.
60.74%
Net income growth above 1.5x CSIQ's 0.00%. David Dodd would check if a unique moat or cost structure secures superior bottom-line gains.
34.50%
EPS growth of 34.50% while CSIQ is zero. Bruce Berkowitz would see if minimal gains can accelerate over time.
34.50%
Diluted EPS growth of 34.50% while CSIQ is zero. Bruce Berkowitz would see if minimal gains can be scaled further for a bigger lead.
-16.12%
Share reduction while CSIQ is at 0.00%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.
-16.12%
Reduced diluted shares while CSIQ is at 0.00%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.
No Data
No Data available this quarter, please select a different quarter.
-100.51%
Negative OCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand a turnaround plan focusing on real cash generation.
-188.03%
Negative FCF growth while CSIQ is at 0.00%. Joel Greenblatt would demand improved cost control or more strategic capex discipline.
1468.44%
10Y revenue/share CAGR above 1.5x CSIQ's 89.20%. David Dodd would confirm if management’s strategic vision consistently outperforms the competitor.
1468.44%
5Y revenue/share CAGR above 1.5x CSIQ's 89.20%. David Dodd would look for consistent product or market expansions fueling outperformance.
1468.44%
3Y revenue/share CAGR above 1.5x CSIQ's 89.20%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
84.42%
OCF/share CAGR of 84.42% while CSIQ is zero. Bruce Berkowitz might see a slight advantage that could compound over time.
84.42%
OCF/share CAGR of 84.42% while CSIQ is zero. Bruce Berkowitz would see if modest momentum can translate into a bigger competitive lead.
84.42%
3Y OCF/share CAGR of 84.42% while CSIQ is zero. Bruce Berkowitz might see if small gains can expand into a broader advantage.
80.68%
Net income/share CAGR at 50-75% of CSIQ's 161.14%. Martin Whitman might question if the firm’s product or cost base lags behind.
80.68%
5Y net income/share CAGR at 50-75% of CSIQ's 161.14%. Martin Whitman might see a shortfall in operational efficiency or brand power.
80.68%
3Y net income/share CAGR 50-75% of CSIQ's 161.14%. Martin Whitman might see a lagging edge in short-term profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
42.45%
AR growth of 42.45% while CSIQ is zero. Bruce Berkowitz wonders if the firm’s additional AR is warranted by strong revenue or potential risk.
26.21%
Inventory growth of 26.21% while CSIQ is zero. Bruce Berkowitz wonders if we anticipate a new wave of demand or risk being stuck with extra product.
92.75%
Asset growth of 92.75% while CSIQ is zero. Bruce Berkowitz checks if modest expansions can create a longer-term lead.
250.95%
BV/share growth of 250.95% while CSIQ is zero. Bruce Berkowitz sees if small growth can compound into a strong advantage.
No Data
No Data available this quarter, please select a different quarter.
-59.76%
Our R&D shrinks while CSIQ invests at 0.00%. Joel Greenblatt checks if we risk falling behind a competitor’s new product pipeline.
-183.30%
We cut SG&A while CSIQ invests at 0.00%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.